Description of Medical ServiceALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Description of Medical ConditionALK-positive advanced NSCLC.
Reason for Application-
Medical Service Type-
Previous Application NumberNot Applicable
PICO ConfirmationFinal Decision Analytic Protocol (DAP) (PDF 585 KB)
Final Decision Analytic Protocol (DAP) (Word 6128 KB)
Public Summary DocumentPublic Summary Document (PDF 247 KB)
Public Summary Document (Word 150 KB)
Meetings for this Application
PASC12 – 13 April 2012
16 – 17 August 2012